Karyopharm Therapeutics Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $99.7M

Website

Clinical Trials

Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults

Phase 1

Terminated

Conditions: Healthy

Interventions: Other: Placebo
Drug: Verdinexor

First Posted Date: 2015-05-01

Last Posted Date: 2023-01-20

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 33

Registration Number: NCT02431364

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Phase 1

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-03-17

Last Posted Date: 2023-01-26

Lead Sponsor: Karyopharm Therapeutics Inc

Registration Number: NCT02389543

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Phase 1

Withdrawn

Conditions: Diabetic Foot Ulcers

Interventions: Drug: Selinexor
Other: Standard-of-Care
Other: Vehicle Gel

First Posted Date: 2015-02-20

Last Posted Date: 2023-01-20

Lead Sponsor: Karyopharm Therapeutics Inc

Registration Number: NCT02367690

Locations: 🇳🇿
South Pacific Clinical Trials, Auckland, New Zealand

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Bortezomib
Drug: Lenalidomide
Drug: Daratumumab
Drug: Carfilzomib
Drug: Ixazomib
Drug: Belantamab Mafodotin
Drug: Mezigdomide
Drug: Elotuzumab
Drug: Clarithromycin

First Posted Date: 2015-01-21

Last Posted Date: 2024-05-07

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 300

Registration Number: NCT02343042

Locations: 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

and more 21 locations

Selinexor Treatment of Refractory Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Dexamethasone

First Posted Date: 2015-01-13

Last Posted Date: 2023-01-26

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 202

Registration Number: NCT02336815

Locations: 🇺🇸
Jonnsson Comprehensive Cancer Center / University of Los Angeles, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center / John Therurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
Sylvester, University of Miami, Miami, Florida, United States

and more 58 locations

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Phase 2

Terminated

Conditions: Peripheral T-cell Lymphoma (PTCL)
Cutaneous T-cell Lymphoma (CTCL)

Interventions: Drug: Selinexor

First Posted Date: 2014-12-11

Last Posted Date: 2023-01-26

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 16

Registration Number: NCT02314247

Locations: 🇦🇺
Concord Repatriation General Hospital (CRGH), Concord, New South Wales, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺
Cabrini Hospital, Malvern, Victoria, Australia

and more 2 locations

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Selinexor

First Posted Date: 2014-08-28

Last Posted Date: 2024-07-24

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 244

Registration Number: NCT02227251

Locations: 🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Virginia Mason Hospital & Medical Center, Seattle, Washington, United States

and more 173 locations

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma

Interventions: Drug: Selinexor (KPT-330)

First Posted Date: 2014-08-11

Last Posted Date: 2023-01-26

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 45

Registration Number: NCT02213133

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States

and more 15 locations

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Selinexor

First Posted Date: 2014-05-26

Last Posted Date: 2023-01-26

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 20

Registration Number: NCT02146833

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

Phase 2

Terminated

Conditions: Richter's Transformation

Interventions: Drug: selinexor

First Posted Date: 2014-05-15

Last Posted Date: 2023-01-26

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 27

Registration Number: NCT02138786

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇩🇪
University of Ulm, Ulm, Baden-Württemberg, Germany

and more 14 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy